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ABSTRACT
Objective: This study aimed to investigate the antithrombotic activity of Tamarindus indica L. extract (TIE) in mouse models (in vivo).
Methods: TIE was orally administered to mice at three different doses for 7 days. TIE-treated mice were used in two experiments of antithrombotic 
activity: An examination of bleeding time following tail cutting and an examination of survival rate after collagen-epinephrine-induced 
thromboembolism. The TIE groups were observed after 7 days of treatment and compared to an aspirin-treated group and a control group.
Results: Treatment with TIE led to a significant increase in bleeding time compared with that in the control group. TIE treatment also protected mice 
from thromboembolic death, significantly increasing survival rates in a dose-dependent manner.
Conclusion: TIE has the potential as an antithrombotic agent against platelet thromboembolism.
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INTRODUCTION
Thrombosis, as one of the risk factors of cardiovascular disease, is the 
formation of a blood clot in an artery or a vein which starts with platelet 
aggregation [1,2]. Deep vein thrombosis (DVT) refers to the formation 
of one or more blood clots in one of the major blood vessels of the body, 
most commonly in the lower limbs. The most serious complication 
that can arise from DVT is a pulmonary embolism (PE), which occurs 
in more than one-third of patients with DVT and often causes sudden 
death [3-5]. Acetylsalicylic acid (ASA), commonly known as aspirin, is 
often used as a platelet aggregation inhibitor agent. ASA inhibits platelet 
aggregation by inhibiting the cyclo-oxygenase (COX) enzyme within the 
COX pathway, thus preventing thrombus formation [6].
In addition to chemical drugs, herbal medicines have been studied for 
their potentials as the antithrombotic agent. Tamarind (Tamarindus 
indica L.), a flowering plant within the family Fabaceae, is a potential 
antithrombotic agent due to its active compound dotriacontanoic 
acid [7]. This compound is one component of D-003, a natural compound 
comprising triacontanoic, dotriacontanoic, and tetradecanoic acid [8,9]. 
Compound D-003 has been tested in vitro on a venous thrombosis model; 
a dose of 200 mg/kg has shown to increase the number of prostacyclin 
molecules (prostaglandin I2 [PgI2]) and reduce thromboxane A2 (TxA2). 
In vivo experiments with D-003 have demonstrated that this compound 
can reduce the formation of venous thrombus at a dose of 400 mg/kg 
in collagen-induced and epinephrine-induced mice [8]. In this study, 
the effects of T. indica L. extract (TIE) were tested in vivo on mice using 
bleeding time and survival rate as metrics of antithrombotic activity.
MATERIALS AND METHODS
Materials
Ethanolic TIE was obtained from the Indonesian Spice and Medicinal 
Crops Research Institute, Bogor. This study used aspirin (Medifarma, 
Indonesia) as a positive control. Carboxymethyl cellulose (CMC) (0.5%; 
Brataco, Indonesia) and saline (Euro-Med, Indonesia) were used as a 
vehicle group (normal and negative control group). Voucher specimens 
were deposited at the Center for Plant Conservation Botanic Gardens 
(No. B-1693/IPH.3./KS/VI/2017).
Total flavonoid and phenolic content assays
Total flavonoid content was measured using the aluminum chloride 
colorimetry method, with absorbance measured at λ=510 nm [10]. 
The total phenolic compound content was measured using the Folin–
Ciocalteu method, with absorbance measured at λ=725 nm [11].
Animals
Male mice (Mus musculus, ddY strain) weighing between 20 and 30 g 
were obtained from the Institute Pertanian Bogor. The use of animals in 
this study was approved by the Ethics Committee of Faculty of Medicine, 
Universitas Indonesia (Number. 232/UN2.F1/ETIK/2017).
Antithrombotic activity tests
Bleeding time test
The treatment of bleeding time was determined according to protocols 
described by Saputri et al. (2017) with the following modifications. 
Mice were divided into the treatment groups shown in Table 1 and 
acclimatized for 1 week. Experimental treatment doses were given 
to mice through oral administration for 7 days. The dose of aspirin 
applied was 80 mg/day [12-14]. Experimental TIE doses were 14, 
28, and 56 mg/20 g mice. Antithrombotic activity was evaluated by 
a bleeding time of 5 h after experimental day 7. The animals were 
anesthetized with ether by inhalation and placed in a horizontal 
position. An approximately 10-mm segment of the tail was amputated 
from each animal using a scalpel. The end of each severed tail was 
immediately immersed in a 15 mL Falcon tube containing isotonic 
saline. The remaining portion of the tail was vertically positioned 
with the tip horizontally placed approximately 2 cm below the body. 
Bleeding observations were conducted for 20 min [12]. Differences in 
bleeding time with TIE treatment were obtained by comparing each 
experimental dosage group to the vehicle group.
Survival rate test
Mice used for survival rate tests were divided into treatment groups 
as shown in Table 2. The survival rate tests were performed 24 h after 
experimental day 7. To induce pulmonary thrombosis, experimental mice 
were injected with a mixture of collagen (700 µg) and epinephrine (42 µg) 
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in the vein of the tail [12,15]. Control mice were administered an injection 
of an isotonic saline solution. After 15 min, the number of dead or paralyzed 
mice was recorded and the survival rate was calculated as follows:
(1 – [number of dead or paralyzed mice]/total number of mice)×100
The increase in survival rate with TIE treatment was analyzed by 
comparing the survival rates of each experimental dosage group to that 
of the vehicle group [12].
Statistical analyses
Analyses were performed using the statistical software SPSS (v.18). 
Homogeneity of the data was tested using the Levene method and 
normality was confirmed using the Shapiro–Wilk method. Normally 
distributed and homogeneous data were analyzed using one-way 
ANOVAs to assess the overall differences among experimental groups. 
Pairwise differences between groups were then examined using least 
significant difference analysis.
RESULTS AND DISCUSSION
Total flavonoid and phenolic content assays
The TIE had a low flavonoid content of 0.002% with no detectable 
phenolic content.
Bleeding time
Compared to the vehicle group, mice treated with single oral doses 
of TIE exhibited significantly increased bleeding times (p≤0.05). The 
experimental group treated with the lowest TIE dose (14 mg/20 g mice) 
exhibited a 99% increase in bleeding time compared to the vehicle 
group. Mice treated with higher TIE doses (28 and 56 mg/20 g mice) 
exhibited increases in bleeding time of 118% and 128%, respectively, 
compared to the vehicle group. The effects of TIE treatments were 
qualitatively similar to the effect of the ASA treatment, which resulted 
in a 125% increase in bleeding time compared to the vehicle group 
(Fig. 1). The increased bleeding times associated with the ASA and 
TIE groups provide evidence of the antithrombotic effect of these 
treatments. Results of the bleeding time tests are shown in Table 3.
Survival rate
TIE-treated experimental group had increased the survival rate in mice. 
TIE had the same result with ASA from 100% induction of collagen-
epinephrine inhibited at doses 2 and 3. The survival rate calculation 
results were shown in Table 4.
Discussion
Analysis of total flavonoid and phenolic content
Tamarind extract has a low flavonoid content. The sample used in 
this study had no detectable phenolic content. Flavonoid compounds 
play a role as antioxidants and also function as antithrombotic agents 
by reducing adenosine diphosphate (ADP)-induced aggregation and 
thrombin. Specifically, flavonoids act as TxA2 receptor antagonists, 
reducing TxA2 which then indirectly inhibits COX-1. In addition, 
flavonoid compounds increase the production of nitric oxide , which is 
important for the inhibition of platelet aggregation [16].
Analysis of bleeding time
The antithrombotic effect of TIE was evaluated by comparing 
the bleeding time of treated animals to animals in the vehicle 
group. Treatments with TIE, which contains the D-003 compound 
dotriacontanoic acid, resulted in significant, dose-dependent increases 
in bleeding time. However, the bleeding times of the TIE-treated 
animals were not significantly different from those of ASA-treated 
animals, indicating that the antithrombotic effect was the same for both 
groups. The largest bleeding time effect was seen in the experimental 
group given the highest dose of TIE (56 mg/20 g mice).
Inhibition of platelet aggregation includes the reduction of TxA2 
formation and prostacyclin (PgI2) enhancement. TxA2 is a potent 
agonist causing the activation of platelets and thrombus formation. 
TxA2 causes irreversible platelet aggregation, vasoconstriction, and 
proliferation of smooth muscle cells [17]. PgI2 is synthesized by PgI2-
synthase in endothelial cells and has an effect as an aggregation inhibitor 
and vasodilator. PgI2 acts to inhibit vasoconstriction and dilate blood 
vessels [8]. When the formation of the thrombus is inhibited, blood flow 
is smooth and bleeding times increase.
In this study, the antithrombotic effects of TIE treatments were similar 
to that of the aspirin treatment. Aspirin inhibits collagen-induced 
platelet aggregation at optimal doses of 81–162 mg/day [18]. Aspirin 
works as an antithrombotic agent by inhibiting the enzyme COX and 
non-COX inhibition. Inhibition of COX-1 will inhibit TxA2 formation 
and stimulate platelet aggregation. In non-COX enzymes, aspirin will 
alter glycoprotein IIb/IIIa receptor function and affect the permeability 
of clots. In addition, aspirin also inhibits acetylates, prothrombin, 
antithrombin, fibrinogen, and factor XIII [18].
Table 1: Treatment groups used for tests of bleeding time in mice
Group Number of mice (n) Dosage  (mg/20 g mice) Bleeding time treatment
Days 1–7 Day 7 (5 h after administration)
Normal 5 CMC 0.5% Tail bleeding assay
ASA 5 0.208 Aspirin
Dose 1 5 14 Tamarind extract (TIE)
Dose 2 5 28
Dose 3 5 56
CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid
Table 2: Treatment of survival rate in mice
Group Number of mice (n) Dosage (mg/20 g mice) Survival rate treatment
Day 1–7 Day 8
Normal 5 CMC 0.5% Saline injection
Negative 5 CMC 0.5% Thrombotic Injection
ASA 5 0.208 Aspirin
Dose 1 5 14 Tamarind extract (TIE)
Dose 2 5 28
Dose 3 5 56
CMC: Carboxymethyl cellulose, ASA: Acetylsalicylic acid
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Analysis of survival rate
A combination of collagen and epinephrine was used to induce 
thrombosis in the experimental animals. Collagen is a major activator of 
secreting granules (serotonin and ADP) which, in turn, activate platelets 
to attach to the subendothelial and form aggregates [12,19]. Epinephrine 
can cause platelet aggregation induced by ADP. Epinephrine is an 
β2-adrenergic agonist which causes a disruption of the exchange 
between potassium ions and sodium and calcium ions, leading to 
hypokalemia [20,21]. Hypokalemia causes stimulation of the muscle 
membrane to be disrupted which can lead to paralysis [22]. The 
injections of collagen and epinephrine caused the deadly effects in mice 
through thromboembolism or vasoconstriction by increased TxA2 and 
Pgs from platelets [17].
The active antithrombotic compound within TIE, the D-003 compound 
dotriacontanoic acid, can inhibit platelet aggregation induced 
by collagen-epinephrine. The D-003 compound inhibits platelet 
aggregation induced by collagen, arachidonic acid, serotonin, and 
ADP [23,24]. In addition, the D-003 compound also inhibits platelet 
aggregation induced by a combination of collagen and epinephrine [8]. 
Prior studies have found that treatment with D-003 inhibits platelet 
aggregation by 55% at a dose of 400 mg/kg BW of mice [8]. The 
dotriacontanoic acid compound (D-003) can also significantly increase 
the survival rate in a dose-dependent manner. TIE is more effective at 
inhibiting platelet aggregation induced by collagen-epinephrine than 
aggregation that is induced by ADP. A prior study, involving treatment 
with the D-003 compound at a dose of 200 mg/kg BW of mice, 
documented that D-003 resulted in a 33% inhibition of ADP-induced 
platelet aggregation and a 39% inhibition of aggregation induced by 
collagen-epinephrine [8].
CONCLUSION
Using in vivo experiments, we demonstrated that TIE has antithrombotic 
potency evidenced by increasing bleeding times and survival rates in 
TIE-treated experimental animals. The greatest antithrombotic potency 
was found at a dose of 56 mg/20 g mice.
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